{"title":"Anti-pig Antibodies in Swine Veterinarian Serum: Implications for Clinical Xenotransplantation","authors":"Guerard Byrne, Christopher McGregor","doi":"arxiv-2404.14658","DOIUrl":null,"url":null,"abstract":"Recent clinical xenotransplantation and human decedent studies demonstrate\nthat clinical hyperacute rejection of genetically engineered porcine organs can\nbe reliably avoided but that antibody mediated rejection continues to limit\ngraft survival. We previously identified porcine glycans and proteins which are\nimmunogenic after cardiac xenotransplantation in nonhuman primates, but the\nclinical immune response to antigens present in glycan depleted triple knockout\n(TKO) donor pigs is poorly understood. In this study we use fluorescence\nbarcoded HEK cells and HEK cell lines expressing porcine glycans (Gal and SDa)\nor proteins (CD9, CD46, CD59, PROCR and ANXA2) to screen antibody reactivity in\nhuman serum from 160 swine veterinarians, a serum source with potential\noccupational immune challenge from porcine tissues and pathogens. High levels\nof anti-Gal IgM were present in all samples and lower levels of anti-SDa IgM\nwere present in 41% of samples. IgM binding to porcine proteins, primarily CD9\nand CD46, previously identified as immunogenic in pig to non-human primate\ncardiac xenograft recipients, was detected in 28 of the 160 swine veterinarian\nsamples. These results suggest that barcoded HEK cell lines expressing porcine\nprotein antigens can be useful for screening human patient serum. A\ncomprehensive analysis of sera from clinical xenotransplant recipients to\ndefine a panel of commonly immunogenic porcine antigens will likely be\nnecessary to establish an array of porcine non-Gal antigens for effective\nmonitoring of patient immune responses and allow earlier therapies to reverse\nantibody mediated rejection.","PeriodicalId":501572,"journal":{"name":"arXiv - QuanBio - Tissues and Organs","volume":"23 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"arXiv - QuanBio - Tissues and Organs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/arxiv-2404.14658","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Recent clinical xenotransplantation and human decedent studies demonstrate
that clinical hyperacute rejection of genetically engineered porcine organs can
be reliably avoided but that antibody mediated rejection continues to limit
graft survival. We previously identified porcine glycans and proteins which are
immunogenic after cardiac xenotransplantation in nonhuman primates, but the
clinical immune response to antigens present in glycan depleted triple knockout
(TKO) donor pigs is poorly understood. In this study we use fluorescence
barcoded HEK cells and HEK cell lines expressing porcine glycans (Gal and SDa)
or proteins (CD9, CD46, CD59, PROCR and ANXA2) to screen antibody reactivity in
human serum from 160 swine veterinarians, a serum source with potential
occupational immune challenge from porcine tissues and pathogens. High levels
of anti-Gal IgM were present in all samples and lower levels of anti-SDa IgM
were present in 41% of samples. IgM binding to porcine proteins, primarily CD9
and CD46, previously identified as immunogenic in pig to non-human primate
cardiac xenograft recipients, was detected in 28 of the 160 swine veterinarian
samples. These results suggest that barcoded HEK cell lines expressing porcine
protein antigens can be useful for screening human patient serum. A
comprehensive analysis of sera from clinical xenotransplant recipients to
define a panel of commonly immunogenic porcine antigens will likely be
necessary to establish an array of porcine non-Gal antigens for effective
monitoring of patient immune responses and allow earlier therapies to reverse
antibody mediated rejection.